Related Experiment Video
Updated: Feb 9, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections
Johan A Kers1, Anthony W DeFusco2, Jae H Park2
1Intrexon Corp., Industrial Products Division, South San Francisco, CA, United States of America.
Abstract:
Lantibiotics continue to offer an untapped pipeline for the development of novel antibiotics. We report here the discovery of a novel lantibiotic for the treatment of C. difficile infection (CDI). The leads were selected from a library of over 300 multiple substitution variants of the lantibiotic Mutacin 1140 (MU1140). Top performers were selected based on testing for superior potency, solubility, manufacturability, and physicochemical and/or metabolic stability in biologically-relevant systems. The best performers in vitro were further evaluated orally in the Golden Syrian hamster model of CDAD. In vivo testing ultimately identified OG716 as the lead compound, which conferred 100% survival and no relapse at 3 weeks post infection. MU1140-derived variants are particularly attractive for further clinical development considering their novel mechanism of action.
More Related Videos
Related Concept Videos
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Purposive Learning
Inclusive Fitness
Goodness-of-Fit Test
Purpose of Health Records I
Here's a breakdown of how health records serve these purposes:
Purpose of Health Records II

